Reaction

Suspected Covid-19 reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,289 reports · 79 co-occurring drugs

As of the last recalculation, Suspected Covid-19 appears in 3,289 FAERS reports alongside 79 co-occurring drug terms. The strongest observed disproportionality signal is RAVULIZUMAB (PRR 31.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ravulizumab	66	31.5	31.7
Infliximab-Dyyb	103	23.0	23.1
Eculizumab	181	22.2	22.3
Diphenhydramine Hydrochloride Capsule, Liquid Filled	55	16.6	16.6
Human Immunoglobulin G	45	14.0	14.0
Ocrelizumab	131	13.9	13.9
Dimenhydrinate	20	11.9	12.0
Agalsidase Beta	15	10.3	10.3
Diphenhydramine	93	9.6	9.6
Asfotase Alfa	15	9.5	9.5
Adrenalinum	54	8.4	8.4
Nevirapine	11	7.7	7.7
Cladribine	10	6.6	6.6
Raltegravir	17	6.5	6.6
Fluticasone Propionate Nasal	31	6.5	6.5
Zinc	25	6.5	6.5
Zinc Chloride	25	6.4	6.4
Epinephrine	64	6.3	6.3
Zinc Gluconate	25	6.1	6.1
Hydrocortisone Sodium Succinate	9	6.1	6.1
Diphenhydramine Hydrochloride	148	5.9	5.9
Infliximab	183	5.6	5.6
Diroximel Fumarate	9	4.8	4.8
Mepolizumab	37	4.8	4.8
Ozanimod Hydrochloride	6	4.6	4.6
Paricalcitol	10	4.5	4.5
Nirmatrelvir And Ritonavir	38	4.5	4.5
Vedolizumab	58	4.3	4.3
Clobetasol Propionate	7	4.3	4.3
Dapagliflozin	21	4.2	4.2
Azelastine	12	4.2	4.2
Tofacitinib	117	4.1	4.1
Tiotropium Bromide Inhalation Spray	7	4.0	4.0
Pegvaliase-Pqpz	5	3.9	3.9
Naproxen Sodium, Dextromethorphan Hydrobromide, Guaifenesin	12	3.7	3.7
Naproxen Sodium, Pseudoephedrine Hydrochloride	12	3.7	3.7
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	24	3.7	3.7
Secukinumab	89	3.6	3.6
Elexacaftor, Tezacaftor, And Ivacaftor	7	3.6	3.6
Cannabidiol	13	3.5	3.5
Canakinumab	6	3.5	3.5
Rivastigmine	10	3.4	3.4
Teduglutide	7	3.3	3.3
Baricitinib	5	3.3	3.3
Ustekinumab	51	3.2	3.2
Benralizumab	10	3.2	3.2
Botulinum Toxin Type A	6	3.1	3.1
Certolizumab Pegol	55	3.0	3.0
Suvorexant	6	2.9	2.9
Ofatumumab	15	2.9	2.9
Clozapine	55	2.8	2.8
Tafamidis	5	2.7	2.7
Crisaborole	4	2.6	2.6
Upadacitinib	31	2.4	2.4
Teriflunomide	17	2.4	2.4
Daratumumab	15	2.4	2.4
Obinutuzumab	6	2.3	2.3
Umeclidinium Bromide And Vilanterol Trifenatate	6	2.3	2.3
Naltrexone Hydrochloride And Bupropion Hydrochloride	3	2.2	2.2
Belimumab	11	2.2	2.2
Risankizumab-Rzaa	28	2.2	2.2
Apalutamide	4	2.2	2.2
Siponimod	3	2.1	2.1
Guselkumab	12	2.1	2.1
Palbociclib	31	2.1	2.1
Palivizumab	5	2.1	2.1
Dornase Alfa	6	1.9	1.9
Peginterferon Beta-1A	4	1.9	1.9
Abemaciclib	6	1.9	1.9
Remdesivir	4	1.9	1.9
Treprostinil	36	1.8	1.8
Osimertinib	9	1.8	1.8
Esketamine Hydrochloride	5	1.8	1.8
Sacubitril And Valsartan	30	1.6	1.6
Galcanezumab-Gnlm	8	1.6	1.6
Sarilumab	6	1.4	1.4
Dupilumab	105	1.4	1.4
Dulaglutide	18	1.3	1.3
Ixekizumab	7	1.2	1.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.